The FDA grants priority review only to drugs that have the potential to offer significant improvement in the treatment of serious conditions.

(...) projected. If approved, Vascepa would be the first drug to manage cardiovascular risk in patients already(...)

Eat less and live longer is the simple message from professor of biology and biogerontologist Prof Steven Austad. File photograph: Jonathan Brady/PA Wire

Austad said: “One thing that came out of studies of them is cardiovascular risk factors. These people are(...)

Novartis executives say the company will file for approval of the drug, LCZ696, in Europe in the first quarter of 2015. The drug could get to patients as early as next year. Photograph: Fabrice Coffrini/AFP/Getty Images

(...)’s prospects.The drug reduced both the risk of dying from cardiovascular causes and of being hospitalised for(...)